

TABLE E-1 Patient Demographics								
Case	Sex	Age (yr)	BMI (kg/m ²)	Diabetes	Arterial Hypertension	Pathogen	Antibiotic Therapy	
							Type	Duration (wk)
1	M	77	24	No	No	Streptococci	Ciprofloxacin	2
2	F	65	31	No	Yes	<i>Proteus mirabilis</i>	Cefuroxime	2
3	M	68	36	Yes	Yes	<i>Enterococcus faecalis</i> , <i>Pseudomonas aeruginosa</i>	Ciprofloxacin, rifampicin, Zyvoxid (linezolid)	6
4	F	74	32	Yes	Yes	<i>Proteus mirabilis</i> , <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i>	Ampicillin/sulbactam, cefuroxime, clindamycin	6
5	F	81	35	No	No	<i>Staphylococcus aureus</i>	Piperacillin-tazobactam	2
6	F	82	31	No	No	Corynebacterium	Ceftriaxone, clindamycin	4
7	M	51	31	No	No	Streptococci	Cefpodoxime	6
8	F	73	40	No	No	<i>Staphylococcus epidermidis</i>	Zyvoxid (linezolid)	4
9	M	67	25	No	Yes	<i>Escherichia coli</i>	Cefpodoxime	4
10	F	82	32	No	No	<i>Staphylococcus aureus</i> , <i>Enterococcus faecalis</i>	Ceftriaxone, clindamycin	4
11	M	59	23	No	No	<i>Staphylococcus aureus</i>	Clindamycin	2
12	F	70	24	No	No	<i>Enterococcus faecalis</i>	Ampicillin/sulbactam	4
13	F	66	33	No	No	Methicillin-resistant <i>Staphylococcus aureus</i>	Vancomycin, rifampicin	6
14	M	56	31	Yes	Yes	Propionibacterium	Ceftriaxone, clindamycin, moxifloxacin	6
15	M	75	40	Yes	Yes	<i>Staphylococcus haemolyticus</i>	Cefuroxime	2
16	F	71	38	No	Yes	<i>Staphylococcus aureus</i>	Ceftazidime	2
17	F	66	30	No	Yes	<i>Pseudomonas aeruginosa</i>	Ciprofloxacin	4
18	F	79	32	No	No	<i>Pseudomonas stutzeri</i>	Amoxicillin/clavulanate	3
19	F	66	33	No	Yes	<i>Staphylococcus aureus</i>	Moxifloxacin	2
20	M	52	44	Yes	Yes	<i>Enterococcus faecalis</i>	Zyvoxid	3
21	F	74	34	No	No	<i>Staphylococcus aureus</i>	Clindamycin	3
22	F	66	23	No	No	<i>Escherichia coli</i>	Ampicillin/sulbactam	4
23	F	69	32	No	Yes	<i>Pseudomonas aeruginosa</i>	Ciprofloxacin	4
24	F	54	25	No	No	<i>Staphylococcus aureus</i>	Ciprofloxacin	4
25	F	61	32	No	No	Methicillin-resistant <i>Staphylococcus aureus</i> , <i>Escherichia coli</i>	Targocid (teicoplanin), Zyvoxid (linezolid)	4
26	F	59	27	No	No	<i>Enterococcus faecalis</i>	Ciprofloxacin	2

TABLE I (continued)

Previous Ops. (no.)	Arthrodesis Nails (no.)	Year of Arthrodesis	Recurrent Infection	Nail Changed	Stable Fistula	Amputation	Follow-up VAS Score (0 = No Pain, 10 = Worst Pain)
9	1	2012	No	No	No	No	10
4	1	2000	Yes	Yes	No	No	1
13	1	2013	Yes	Yes	Yes	No	5
9	2	2013	Yes	Yes	Yes	No	10
7	3	2012	No	No	No	No	7
4	1	2005	Yes	Yes	No	No	4
6	1	2004	Yes	No	No	Yes	3
5	1	2012	No	No	No	No	3
9	1	2009	No	No	No	No	5
3	1	2009	No	No	No	No	9
3	1	2005	No	No	No	No	2
6	1	2009	No	No	No	No	3
3	1	2005	Yes	No	No	No	7
8	1	2013	Yes	Yes	No	No	2
2	1	2009	Yes	Yes	No	Yes	5
6	2	2012	Yes	No	No	No	8
2	1	2005	Yes	Yes	No	No	10
4	1	2006	No	No	No	No	8
11	1	2011	No	No	No	No	9
8	2	2009	Yes	Yes	No	No	10
4	1	2009	No	No	No	No	3
5	1	2008	No	No	No	No	6
6	2	2011	Yes	Yes	No	No	5
8	1	2010	No	No	No	No	7
3	1	2002	Yes	No	No	Yes	8
3	1	1997	No	No	No	No	7

TABLE E-2 Functional Outcomes		
Score	Points*	% of Max.†
Lysholm	17 ± 12	17
KSS	40 ± 25	40
WOMAC	39 ± 16	39
KOOS	71 ± 17	42
SF-36	29 ± 23	29

*The values are given as the mean and standard deviation. †The maximum number of points was 100 for all scores except the KOOS, for which it was 168.

TABLE E-3 Predictors of Reinfection		
	No. of Patients (of 13 with Infection)	P Value*
Obesity	13	<0.001
Diabetes mellitus	5	0.013
Arterial hypertension	11	0.005

*Chi-square test.